AFMD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

82.99M

Low

Amount

EV/EBITDA(TTM)

Total Shares

-8.23M

EV/OCF(TTM)

P/S(TTM)

427.00

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

Events Timeline

(ET)

2025-05-14

06:47:08

Affimed receives Nasdaq delisting notice

2025-05-14

06:19:10

Affimed downgraded to Neutral from Buy at H.C. Wainwright

2025-05-13 (ET)

2025-05-13

08:25:52

Affimed announces filing for opeing of insolvency proceedings

2025-04-21 (ET)

2025-04-21

06:33:12

Affimed receives Nasdaq notice of non-compliance

News

3.0

2025-05-20TipRanks

3 Penny Stocks to Watch Now, 5/20/25

2.0

2025-05-19Benzinga

Dow Tumbles 200 Points; ZIM Integrated Shipping Services Posts Upbeat Earnings

9.0

2025-05-19Benzinga

Why Novavax Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

4.5

2025-05-16Benzinga

US Stocks Edge Higher; Consumer Sentiment Falls In May

9.0

2025-05-14SeekingAlpha

Immuno-oncology company Affimed to be delisted from Nasdaq after insolvency filing

4.0

2025-05-13Benzinga

Wells Fargo Downgrades Affimed to Equal-Weight, Lowers Price Target to $0.1

1 Analyst Rating

Wall Street analysts forecast AFMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AFMD is 0.39 USD with a low forecast of 0.39 USD and a high forecast of 0.39 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

1 Hold

0 Sell

Hold

Current: 0.000

Low

0.39

Averages

0.39

High

0.39

Current: 0.000

Low

0.39

Averages

0.39

High

0.39

Leerink

Shawn Leland

Outperform

Market Perform

downgrade

Al Analysis

2025-05-13

Reason

Leerink

Shawn Leland

Price Target

Al Analysis

2025-05-13

downgrade

Outperform

Market Perform

Reason

Leerink downgraded Affimed to Market Perform from Outperform with a price target of 39c, down from $5. The firm no longer believes it is likely the company will secure funding to continue development of their three clinical innate cell engager programs. Despite promising clinical signals for all three programs, an eight-month active search under their new CEO, Shawn Leland, has not attracted a strategic nor financial partner. Leerink suspects the signals look less promising upon diligence by partners and/or the market opportunities are simply not large enough to justify investment. Further, for the firm, new CBER leadership at FDA reduces the probability of accelerated approval for any cell therapy, including acimtamig + AB101 + IL-2, a regimen which also faces contribution-of-components regulatory questions.

Wells Fargo

Overweight -> Equal Weight

downgrade

$11

2025-05-13

Reason

Wells Fargo

Price Target

$11

2025-05-13

downgrade

Overweight -> Equal Weight

Reason

Wells Fargo downgraded Affimed to Equal Weight from Overweight with a price target of 10c, down from $11.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AFMD

Unlock Now

Valuation Metrics

The current forward P/E ratio for Affimed NV (AFMD.O) is -0.13, compared to its 5-year average forward P/E of -4.39. For a more detailed relative valuation and DCF analysis to assess Affimed NV 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.39

Current PE

-0.13

Overvalued PE

1.11

Undervalued PE

-9.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.83

Current EV/EBITDA

0.08

Overvalued EV/EBITDA

1.52

Undervalued EV/EBITDA

-5.18

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

14.42

Current PS

0.93

Overvalued PS

20.19

Undervalued PS

8.64

Financials

Al Analysis

Annual

Quarterly

Trading Trends

People Also Watch

Frequently Asked Questions

What is Affimed NV (AFMD) stock price today?

The current price of AFMD is 0 USD — it has increased 0 % in the last trading day.

What is Affimed NV (AFMD)'s business?

What is the price predicton of AFMD Stock?

Wall Street analysts forecast AFMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AFMD is0.39 USD with a low forecast of 0.39 USD and a high forecast of 0.39 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Affimed NV (AFMD)'s revenue for the last quarter?

Affimed NV revenue for the last quarter amounts to 155.00K USD, decreased -92.10 % YoY.

What is Affimed NV (AFMD)'s earnings per share (EPS) for the last quarter?

Affimed NV. EPS for the last quarter amounts to -0.94 USD, decreased -42.33 % YoY.

How many employees does Affimed NV (AFMD). have?

Affimed NV (AFMD) has 76 emplpoyees as of January 17 2026.

What is Affimed NV (AFMD) market cap?

Today AFMD has the market capitalization of 82.99M USD.

AFMD Overview

AFMD Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

People Also Watch

Frequently Asked Questions

What is Affimed NV (AFMD) stock price today?

What is Affimed NV (AFMD)'s business?

What is the price predicton of AFMD Stock?

What is Affimed NV (AFMD)'s revenue for the last quarter?

What is Affimed NV (AFMD)'s earnings per share (EPS) for the last quarter?

How many employees does Affimed NV (AFMD). have?

What is Affimed NV (AFMD) market cap?